Kim Drapkin

Kim Drapkin is the current Chief Financial Officer at Jounce Therapeutics. Kim has also served as a Board Member and Chair of the Audit Committee at Proteostasis Therapeutics, Inc. from February 2019 to December 2020. Prior to their current positions, Drapkin was the Principal and Founder of KCD Financial Consultants LLC from August 2009 to August 2015. In this role, they served as Interim CFO at a number of biotechnology start-ups, including Avila Therpeutics, Inc., Blueprint Medicines Corporation, Deuterx LLC, Eleven Biotherapeutics, Inc., Jounce Therapeutics, Inc., NinePoint Medical, Inc., Permeon Biologics, Inc., Voyager Therapeutics, Inc., and Warp Drive Bio LLC. From January 2005 to August 2009, Drapkin served as the Chief Financial Officer at EPIX Pharmaceuticals (formerly Predix Pharmaceuticals). From January 1995 to December 2005, they served as the Director of Finance at Millennium Pharmaceuticals.

Kim Drapkin has a Bachelor’s Degree in Accounting from Babson College and is a Certified Public Accountant. Kim also has a certification from Harvard Business School Executive Education in Women on Boards and Women's Leadership Forum.

They are on a team with Dmitri Wiederschain - Chief Scientific Officer, Allison Nance - Senior Vice President, Regulatory Affairs, Quality Assurance & Medical Writing, and Hugh Cole - Chief Operating Officer. Their manager is Richard Murray , President & CEO.